Anticancer agent 7
Anticancer agent 7 (Example 5) modulates PP2A, and induces FOXOl transcription factor translocation to the nucleus. Anticancer agent 7 inhibits the proliferation of H1650 lung cancer cell with an IC50 of 5 μM[1].
Product Specifications
CAS Number
[2088956-21-0]
UNSPSC
12352005
Target
FOXO; Phosphatase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-7.html
Purity
99.26
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@@H]1[C@@](COC[C@H]1NS(=O)(C2=CC=C(C=C2)OC(F)(F)F)=O)([H])N3C4=CC=C(Cl)C=C4C5=CC(Cl)=CC=C53
Molecular Formula
C24H19Cl2F3N2O5S
Molecular Weight
575.38
References & Citations
[1]Michael Ohlmeyer, et al. Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents. WO2017044569A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PDE7B (cAMP-specific 3',5'-cyclic Phosphodiesterase 7B) (FITC)
PDE7B (cAMP-specific 3',5'-cyclic Phosphodiesterase 7B) (FITC)
